Multiple media outlets reported on the 25th that BAL0891, an anti-cancer drug candidate under development by SillaJen (215600), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) as a treatment for acute myeloid leukemia (AML).

■ BAL0891, a Dual-Target Anti-Cancer Drug Candidate Inhibiting Both TTK and PLK1

BAL0891 is a therapeutic candidate with a dual-target mechanism that simultaneously inhibits two proteins, TTK and PLK1, which play key roles in the process of cancer cell division. A global Phase 1 clinical trial is currently underway in patients with solid tumors and hematologic cancers.

■ Rights Secured via Basilea, Then Consolidated Through Dutch Biotech Company

Regarding how the rights were secured, SillaJen acquired the rights to BAL0891 from Swiss pharmaceutical company Basilea in 2022. Subsequently, last year, the company additionally acquired the patents and related rights to the substance from a Netherlands-based biotech company, thereby consolidating its rights.

Accordingly, this is a time when market trends and stock price movements should be closely monitored.

[This article is reference information for investment decisions and is not intended to solicit investment or recommend specific stocks. The final judgment and responsibility for investments rest with the investor. This article was written with AI assistance.]